Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Evaxion Biotech A/S EVAX

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is... see more

NDAQ:EVAX - Post Discussion

Evaxion Biotech A/S > Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales | Benz
View:
Post by whytestocks on Jan 24, 2024 10:00am

Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales | Benz

Just In: $EVAX Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales | BenzingaU.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Wednesday.Following the market opening Wednesday,...EVAX - Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities